miR‑125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway

Tang,Hao; Li,Rong‑Ping; Liang,Ping; Zhou,Ya‑Long; Wang,Guang‑Wei

doi:10.3892/ol.2015.3264

miR‑125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway

Authors:
- Hao Tang
- Rong‑Ping Li
- Ping Liang
- Ya‑Long Zhou
- Guang‑Wei Wang
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, The 187th Hospital of Chinese People's Liberation Army, Haikou, Hainan 571159, P.R. China, Department of Emergency, The 187th Hospital of Chinese People's Liberation Army, Haikou, Hainan 571159, P.R. China, Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Third Military Medical University, Chongqing 400038, P.R. China
Published online on: May 26, 2015 https://doi.org/10.3892/ol.2015.3264
Pages: 681-686
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In order to explore the regulation of the invasive ability of hepatocellular carcinoma cells and the underlying mechanism, mimics sequences of microRNA (miR)‑125a (miR‑125a‑3p/5p) and scramble sequences (miR‑125a‑3p‑s/5p‑s) were transfected into human hepatocellular carcinoma cell lines, HCC‑LM3 and HepG2, and the non‑malignant epithelioid hepatic cell line QZG. To inhibit and upregulate the expression of miR‑125a individually. Protein expression was detected by western blotting, and the cell proliferation and migration abilities were evaluated by soft agar colony formation and Transwell assay, respectively. It was revealed that the expression of miR‑125a was downregulated in HepG2 and HCC‑LM3 cells compared with that of QZG cells, and expression was markedly lower in HCC‑LM3 cells than that in HepG2 cells (P<0.01). The colony formation and migration rates of the cells transfected with miR‑125a‑3p/5p were decreased compared with negative controls, but were increased in cells transfected with miR‑125a‑3p‑3/5p‑s (P<0.01). The protein and messenger RNA expression of phosphoinositide 3‑kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) was decreased following transfection with miR‑125a‑5p, whereas expression was increased compared with negative controls following transfection with miR‑125a‑5p‑s (P<0.01). Furthermore, the proliferation and migration abilities of cells were attenuated following inhibition of the PI3K/AKT/mTOR pathway by LY294002. The results of the present study indicated that miR‑125a inhibits the invasive ability of hepatocellular carcinoma cells via regulation of the PI3K/AKT/mTOR pathway.

View Figures

View References

1	Hao J and Chen WQ: The 2012 Chinese cancer registry annual report. Military Medical Science Press; Beijing, China: pp. 27–60. 2012, (In Chinese).
2	Giannini EG, Farinati F, Ciccarese F, et al Italian Liver Cancer (ITA.LI.CA.) group: Prognosis of untreated hepatocellular carcinoma. Hepatology. 61:184–190. 2015. View Article : Google Scholar : PubMed/NCBI
3	Deng GL, Zeng S and Shen H: Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World J Hepatol. 7:787–798. 2015. View Article : Google Scholar : PubMed/NCBI
4	Liu X, Zhou Y, Liu X, et al: MPHOSPH1: A potential therapeutic target for hepatocellular carcinoma. Cancer Res. 74:6623–6634. 2014. View Article : Google Scholar : PubMed/NCBI
5	Zhou D, Huang C, Kong L and Li J: Novel therapeutic target of hepatocellular carcinoma by manipulation of macrophage colony-stimulating factor/tumor-associated macrophages axis in tumor microenvironment. Hepatol Res. 44:E318–E319. 2014. View Article : Google Scholar : PubMed/NCBI
6	Galuppo R, Ramaiah D, Ponte OM and Gedaly R: Molecular therapies in hepatocellular carcinoma: What can we target? Dig Dis Sci. 59:1688–1697. 2014. View Article : Google Scholar : PubMed/NCBI
7	Lee TK, Cheung VC, Lu P, et al: Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology. 60:179–191. 2014. View Article : Google Scholar : PubMed/NCBI
8	Gao G, Gay HA, Chernock RD, et al: A microRNA expression signature for the prognosis of oropharyngeal squamous cell carcinoma. Cancer. 119:72–80. 2013. View Article : Google Scholar : PubMed/NCBI
9	Chen S, Xue Y, Wu X, et al: Global microRNA depletion suppresses tumor angiogenesis. Genes Dev. 28:1054–1067. 2014. View Article : Google Scholar : PubMed/NCBI
10	Vriens MR, Weng J, Suh I, et al: MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer. 118:3426–3432. 2012. View Article : Google Scholar : PubMed/NCBI
11	van Kouwenhove M, Kedde M and Agami R: MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer. 11:644–656. 2011. View Article : Google Scholar : PubMed/NCBI
12	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
13	Scott GK, Goga A, Bhaumik D, et al: Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem. 282:1479–1486. 2007. View Article : Google Scholar : PubMed/NCBI
14	Cowden DK, Dahl R, Kruichak JN and Hudson LG: The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia. 11:1208–1215. 2009. View Article : Google Scholar : PubMed/NCBI
15	Cortez MA, Nicoloso MS, Shimizu M, et al: miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosomes Cancer. 49:981–990. 2010. View Article : Google Scholar : PubMed/NCBI
16	Jiang L, Huang Q, Zhang S, et al: Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer. 10:3182010. View Article : Google Scholar : PubMed/NCBI
17	Wang G, Mao W, Zheng S and Ye J: Epidermal growth factor receptor-regulated miR-125a-5p - a metastatic inhibitor of lung cancer. FEBS J. 276:5571–5578. 2009. View Article : Google Scholar : PubMed/NCBI
18	Jiang L, Zhang Q, Chang H, et al: hsa-miR-125a-5p enhances invasion in non-small cell lung carcinoma cell lines by upregulating rock-1. Zhongguo Fei Ai Za Zhi. 12:1069–1073. 2009.(In Chinese). PubMed/NCBI
19	Hashiguchi Y, Nishida N, Mimori K, et al: Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathological significance. Int J Oncol. 40:1477–1482. 2012.PubMed/NCBI
20	Coppola N, Potenza N, Pisaturo M, et al: Liver microRNA hsa-miR-125a-5p in HBV chronic infection: Correlation with HBV replication and disease progression. PLoS One. 8:e653362013. View Article : Google Scholar : PubMed/NCBI
21	Potenza N, Papa U, Mosca N, et al: Human microRNA hsa-miR-125a-5p interferes with expression of hepatitis B virus surface antigen. Nucleic Acids Res. 39:5157–5163. 2011. View Article : Google Scholar : PubMed/NCBI
22	Bi Q, Tang S, Xia L, et al: Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One. 7:e401692012. View Article : Google Scholar : PubMed/NCBI
23	Martini M, De Santis MC, Braccini L, et al: PI3K/AKT signaling pathway and cancer: An updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
24	Yan-nan B, Zhao-yan Y, Li-xi L, et al: MicroRNA-21 accelerates hepatocyte proliferation in vitro via PI3K/AKT signaling by targeting PTEN. Biochem Biophys Res Commun. 443:802–807. 2014. View Article : Google Scholar : PubMed/NCBI
25	Wang RY, Chen L, Chen HY, et al: MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients. Gastroenterology. 145:1436–1448. 2013. View Article : Google Scholar : PubMed/NCBI
26	Abbud-Antaki RA, Marhefka JN, DeLuca AL and Zuromskis MP: The cancer biochip system: A functional genomic assay for anchorage-independent three-dimensional breast cancer cell growth. Horm Cancer. 3:261–270. 2012. View Article : Google Scholar : PubMed/NCBI
27	Guadamillas MC, Cerezo A and Del PM: Overcoming anoikis-pathways to anchorage-independent growth in cancer. J Cell Sci. 124:3189–3197. 2011. View Article : Google Scholar : PubMed/NCBI
28	Okabe H, Ishimoto T, Mima K, et al: CD44s signals the acquisition of the mesenchymal phenotype required for anchorage-independent cell survival in hepatocellular carcinoma. Br J Cancer. 110:958–966. 2014. View Article : Google Scholar : PubMed/NCBI
29	Marshall J: Transwell invasion assays. Methods Mol Biol. 769:97–110. 2011.PubMed/NCBI
30	Janku F, Kaseb AO, Tsimberidou AM, et al: Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget. 5:3012–3022. 2014.PubMed/NCBI